How This Evidence Evolved
Gestational Diabetes Screening
From O'Sullivan criteria through HAPO continuous risk to the one-step vs two-step debate
Timeline
Early observations and pilot data that first suggested a new direction
Landmark RCTs and pivotal trials that established the evidence base
Follow-up studies, subgroup analyses, and real-world validation
Serious perinatal complications (composite)
Primary neonatal composite: treatment 32.4% vs usual care 37.0% (P=0.14; no significant reduction)
Diagnostic thresholds for GDM
Primary neonatal composite: treatment 32.4% vs usual care 37.0% (P=0.14)
GDM diagnosis: one-step 16.5% vs two-step 8.5% (RR 1.94, 97.5% CI 1.79–2.11)
Integration into clinical practice guidelines and recommendations
75-g OGTT at 24–28 weeks if diabetes/GDM not already diagnosed; ≥1 threshold: fasting ≥5.1, 1h ≥10.0, 2h ≥8.5 mmol/L.
For low-risk pregnancy: FIGO 2015 recommends one-step 75-g OGTT with IADPSG criteria.
Current standard of care and ongoing research directions
Landmark Trials in This Story
CRITERIA FOR THE ORAL GLUCOSE TOLERANCE TEST IN PREGNANCY.
Oral glucose-tolerance criteria in pregnancy
Hyperglycemia and adverse pregnancy outcomes
Birthweight, caesarean, neonatal glucose, cord C-peptide
Effect of treatment of gestational diabetes mellitus on pregnancy outcomes
Serious perinatal complications (composite)
A multicenter, randomized trial of treatment for mild gestational diabetes.
Primary neonatal composite: treatment 32.4% vs usual care 37.0% (P=0.14; no significant reduction)
International association of diabetes and pregnancy study groups recommendations on the diagnosis and classification of hyperglycemia in pregnancy
Diagnostic thresholds for GDM
A multicenter, randomized trial of treatment for mild gestational diabetes.
Primary neonatal composite: treatment 32.4% vs usual care 37.0% (P=0.14)
A Pragmatic, Randomized Clinical Trial of Gestational Diabetes Screening.
GDM diagnosis: one-step 16.5% vs two-step 8.5% (RR 1.94, 97.5% CI 1.79–2.11)
NIH consensus development conference: diagnosing gestational diabetes mellitus.
The 2013 independent panel recommended continuing 50-g screening followed by a 100-g OGTT after an abnormal screen; not NIH or federal policy.
Explore the evidence yourself
Ask AttendMe about any trial, guideline, or clinical question. Evidence-ranked answers from 3.7M+ peer-reviewed articles.